Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,297 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Induction Phase Clear all
Completed Phase 2 Interventional

Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

NCT01367574
View directory record Official record
Conditions
Bowel Dysfunction
Interventions
SC MNTX
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 23, 2026, 8:50 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Smoked Nicotine Induced Changes in Hormone Function, Mood States and Behaviors

NCT01636323
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Nicotine
Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Oct 23, 2026, 8:50 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

NCT04302324
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions
Daratumumab SC, Clarithromycin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 23, 2026, 8:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

NCT01837862
View directory record Official record
Conditions
Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma, Pleomorphic Xanthoastrocytoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma, Diffuse Intrinsic Pontine Glioma, DIPG, Low-grade Glioma, Brainstem Glioma
Interventions
Mebendazole, Vincristine, Carboplatin, Temozolomide, Bevacizumab, Irinotecan
Drug
Lead sponsor
Julie Krystal
Other
Eligibility
1 Year to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 8:50 AM EDT
Terminated Phase 2 Interventional Results available

The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment

NCT01655823
View directory record Official record
Conditions
Pain, Peripheral Neuropathy, Neuropathic Pain
Interventions
Placebo, Tetrodotoxin
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Fountain Valley, California • Laguna Hills, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

NCT01566435
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, Cisplatin, Fluorouracil, Intensity modulated radiation therapy, Cetuximab, Quality-of-life assessment
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4

NCT00497146
View directory record Official record
Conditions
Chronic Kidney Disease, Left Ventricular Hypertrophy
Interventions
paricalcitol, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
30
States / cities
Phoenix, Arizona • Tempe, Arizona • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Games to Overcome Late Life Depression

NCT02229188
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Problem Solving Therapy, Evolution, Words
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease

NCT02394028
View directory record Official record
Conditions
Crohn Disease
Interventions
Etrolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
62
States / cities
Arcadia, California • La Jolla, California • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

NCT03463265
View directory record Official record
Conditions
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Interventions
nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab, nab-sirolimus + lomustine, nab-sirolimus + marizomib (MRZ), nab-sirolimus + temozolomide + radiotherapy
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Fullerton, California • Newport Beach, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 1 Interventional

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

NCT06050928
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Oral EP262
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Tampa, Florida • Boise, Idaho • Owensboro, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 23, 2026, 8:50 AM EDT
Terminated Phase 2 Interventional Results available

Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

NCT03396471
View directory record Official record
Conditions
Carcinoma, Unspecified Site
Interventions
Pembrolizumab, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 23, 2026, 8:50 AM EDT
Completed No phase listed Observational

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

NCT00003863
View directory record Official record
Conditions
Lymphoma
Interventions
comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization, gene rearrangement analysis
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
69
States / cities
Anniston, Alabama • La Jolla, California • San Diego, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 23, 2026, 8:50 AM EDT
Active, not recruiting Phase 2 Interventional

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04329325
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive
Interventions
Blinatumomab, dasatinib, dexamethasone, methotrexate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

NCT04208958
View directory record Official record
Conditions
Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer
Interventions
VE800, Nivolumab, Vancomycin Oral Capsule
Biological · Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

NCT00974233
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Bendamustine, Rituximab, Lenalidomide
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
10
States / cities
Green Bay, Wisconsin • Janesville, Wisconsin • La Crosse, Wisconsin + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 2 Interventional

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

NCT01467115
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
Radiation · Drug · Biological
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

NCT00126555
View directory record Official record
Conditions
Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Interventions
Gefitinib, Radiotherapy, Conventional surgery, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 23, 2026, 8:50 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

NCT04593784
View directory record Official record
Conditions
Healthy
Interventions
Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device)
Drug · Device
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn

NCT01037452
View directory record Official record
Conditions
Heartburn
Interventions
Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg, Lansoprazole, Calcium carbonate/magnesium hydroxide, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 1 Interventional

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

NCT02228772
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, T-cell Adult Acute Lymphoblastic Leukemia
Interventions
MLN 9708, Vincristine, Cytarabine, Doxorubicin, Mercaptopurine, Cyclophosphamide, Methotrexate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
51 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo

NCT00775645
View directory record Official record
Conditions
Breast Cancer, Chemotherapeutic Agent Toxicity, Fatigue, Neuropathy, Neurotoxicity
Interventions
acetyl-L-carnitine hydrochloride, placebo
Dietary Supplement · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
295
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 196 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 2 Interventional

UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

NCT00064272
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ginger extract, placebo
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
5
States / cities
South Bend, Indiana • Ann Arbor, Michigan • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 23, 2026, 8:50 AM EDT
Terminated Phase 3 Interventional Results available

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

NCT00616902
View directory record Official record
Conditions
Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular
Interventions
paricalcitol injection 4 mcg/mL, Placebo Injection 4 mcg/mL
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
29
States / cities
Phoenix, Arizona • Tempe, Arizona • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 23, 2026, 8:50 AM EDT